United States Biotechnology & Medical Research

Urogen Pharma Ltd (URGN)

Track

In the last 90 days, Urogen Pharma Ltd. saw two insider transactions, both sales totaling $600,048. Mark Schoenberg, Chief Medical Officer, was involved in multiple sales, including planned and proposed sales. The company's stock has performed strongly, up 39.1% in 90 days, and is near its 52-week high. The last earnings report missed expectations.
Stock chart
Ticker: URGN Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Schoenberg Mark
Chief Medical Officer
2 sales — total 600,048 USD
Planned sale 8 May 2026
Value US$1,946,276.96 | Price 376.76 | Shares 24,313
Proposed sale 8 May 2026
Value US$4,091,591.08 | Price 126.59 | Shares 54,408
Sale 3 Feb 2026
Value US$4,946,869.12 | Price 224.69 | Shares 55,884
Sale 3 Feb 2026
Value US$3,027,928.62 | Price 151.00 | Shares 91,796
Sale 3 Feb 2026
Value US$52,257.26 | Price 19.69 | Shares 2,654
Sale 3 Feb 2026
Value US$72,577.34 | Price 19.69 | Shares 3,686
Sale 3 Feb 2026
Value US$36,288.67 | Price 19.69 | Shares 1,843
Sale 3 Feb 2026
Value US$72,577.34 | Price 19.69 | Shares 3,686
Sale 3 Feb 2026
Value US$36,288.67 | Price 19.69 | Shares 1,843
Sale 3 Feb 2026
Value US$36,308.36 | Price 19.69 | Shares 1,844
Proposed sale 2 Feb 2026
Value US$261,460.13 | Price 19.61 | Shares 13,333
Planned sale 19 Nov 2025
Value US$250,000.00 | Price 25.00 | Shares 10,000
Proposed sale 19 Nov 2025
Value US$250,005.00 | Price 25.00 | Shares 10,000
Sale 8 Oct 2025
Value US$37,120.55 | Price 16.85 | Shares 2,203
Proposed sale 8 Sep 2025
Value US$16,444.48 | Price 18.88 | Shares 871
Sale 8 Sep 2025
Value US$16,644.81 | Price 19.11 | Shares 871
Proposed sale 8 Sep 2025
Value US$28,697.60 | Price 18.88 | Shares 1,520
Sale 8 Sep 2025
Value US$29,047.20 | Price 19.11 | Shares 1,520
Sale 11 Aug 2025
Value US$176,900.00 | Price 17.69 | Shares 10,000
Sale 28 Jul 2025
Value US$98,551.86 | Price 19.14 | Shares 5,149
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-11 2026-05-08 PlS Planned sale
2.2
Schoenberg Mark

Chief Medical Officer

Officer
24,313 +9.7%
376.76
US$1,946,277 		24,313 +9.7% 376.76 US$1,946,277
2026-05-08 2026-05-08 PrS Proposed sale
2.2
Schoenberg Mark

Officer

Officer
54,408
126.59
US$4,091,591 		54,408 126.59 US$4,091,591
2026-02-11 2026-02-03 S Sale
2.1
Smith Jason Drew

General Counsel

Officer
55,884 -20.3%
224.69
US$4,946,869 		55,884 -20.3% 224.69 US$4,946,869
2026-02-11 2026-02-03 S Sale
2.1
Smith Jason Drew

General Counsel

Officer
1,608 -3.0%
19.69
US$31,662 		1,608 -3.0% 19.69 US$31,662
2026-02-11 2026-02-03 S Sale
2.1
Smith Jason Drew

General Counsel

Officer
2,654 -4.8%
19.69
US$52,257 		2,654 -4.8% 19.69 US$52,257
2026-02-04 2026-02-03 S Sale
2.2
Schoenberg Mark

Chief Medical Officer

Officer
3,686 -2.5%
19.69
US$72,577 		3,686 -2.5% 19.69 US$72,577
2026-02-04 2026-02-03 S Sale
2.2
Schoenberg Mark

Chief Medical Officer

Officer
1,843 -1.2%
19.69
US$36,289 		1,843 -1.2% 19.69 US$36,289
2026-02-04 2026-02-03 S Sale
2.2
Schoenberg Mark

Chief Medical Officer

Officer
3,686 -2.5%
19.69
US$72,577 		3,686 -2.5% 19.69 US$72,577
2026-02-04 2026-02-03 S Sale
2.2
Schoenberg Mark

Chief Medical Officer

Officer
1,843 -1.2%
19.69
US$36,289 		1,843 -1.2% 19.69 US$36,289
2026-02-04 2026-02-03 S Sale
2.2
Schoenberg Mark

Chief Medical Officer

Officer
1,844 -1.2%
19.69
US$36,308 		1,844 -1.2% 19.69 US$36,308
2026-02-03 2026-02-02 PrS Proposed sale
2.2
Schoenberg Mark

Officer

Officer
13,333
19.61
US$261,460 		13,333 19.61 US$261,460
2025-11-20 2025-11-19 PlS Planned sale
2.2
Schoenberg Mark

Chief Medical Officer

Officer
10,000 -6.7%
25.00
US$250,000 		10,000 -6.7% 25.00 US$250,000
2025-11-19 2025-11-19 PrS Proposed sale
2.2
Schoenberg Mark

Officer

Officer
10,000
25.00
US$250,005 		10,000 25.00 US$250,005
2025-10-09 2025-10-08 S Sale
2.2
Degnan Chris

Chief Financial Officer

Officer
2,203 -49.1%
16.85
US$37,121 		2,203 -49.1% 16.85 US$37,121
2025-09-09 2025-09-08 PrS Proposed sale
2.2
Schoenberg Mark

Officer

Officer
871
18.88
US$16,444 		871 18.88 US$16,444
2025-09-09 2025-09-08 PrS Proposed sale
2.1
Smith Jason Drew

Officer

Officer
1,520
18.88
US$28,698 		1,520 18.88 US$28,698
2025-09-09 2025-09-08 S Sale
2.2
Schoenberg Mark

Chief Medical Officer

Officer
871 -0.6%
19.11
US$16,645 		871 -0.6% 19.11 US$16,645
2025-09-09 2025-09-08 S Sale
2.1
Smith Jason Drew

General Counsel

Officer
1,520 -3.4%
19.11
US$29,047 		1,520 -3.4% 19.11 US$29,047
2025-08-13 2025-08-11 S Sale
2.2
Schoenberg Mark

Chief Medical Officer

Officer
10,000 -6.3%
17.69
US$176,900 		10,000 -6.3% 17.69 US$176,900
2025-07-30 2025-07-28 S Sale
2.2
Schoenberg Mark

Chief Medical Officer

Officer
5,149 -3.2%
19.14
US$98,552 		5,149 -3.2% 19.14 US$98,552
Explore more

More insider trading research around Urogen Pharma Ltd

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America